693PPOLO: Time to treatment discontinuation and subsequent therapies following maintenance olaparib for patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC)
Van Cutsem, E, Golan, T, Hammel, P, Reni, M, Macarulla, T, Hall, M J, Park, J O, Hochhauser, D, Arnold, D, Oh, D-Y, Reinacher-Schick, A, Tortora, G, Algül, H, O’Reilly, E M, McGuinness, D, Cui, K Y, SVolume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz247.020
Date:
October, 2019
File:
PDF, 94 KB
2019
File converter
More search results
More benefits 
